Genomic signatures in T-cell lymphoma

How can these improve precision in diagnosis and inform prognosis?

Javeed Iqbal, Ryan Wilcox, Hina Naushad Qureishi, Joseph Rohr, Tayla B. Heavican, Chao Wang, Alyssa Bouska, Kai Fu, Wing C. Chan, Julie Marie Vose

Research output: Contribution to journalArticle

25 Citations (Scopus)

Abstract

The novel genetic information gained from genome-wide high throughput techniques has greatly improved our understanding of peripheral T-cell lymphoma (PTCL). PTCL consists of numerous distinct entities and is currently diagnosed using a combination of clinical and morphologic features and immunophenotyping together with limited molecular assays leading to an often fragmented, complicated diagnostic system. The diagnosis of many cases is challenging even for expert hematopathologists and more than a third of the cases cannot be further classified and thus put into the PTCL-NOS category. Gene expression profiling (GEP) has significantly improved the molecular classification of PTCLs and identified robust molecular signatures for common nodal subtypes of PTCL including angioimmunoblastic T-cell lymphoma (AITL), anaplastic T-cell lymphoma (ALCL), adult T-cell leukemia/lymphoma (ATLL) and extra-nodal NK/T cell lymphoma (ENKTL). These studies also led to identification of novel molecular subtypes with distinct prognosis, that otherwise could not be identified by conventional methods. Integration of massive sequencing strategies and gene expression has characterized driver genetic alterations in common subtypes like AITL, ALCL, ENKTL and other PTCLs. These studies have identified oncogenic pathways and genes affected in specific disease subtypes that can be potentially targeted by specific therapies. Novel treatment options with FDA approved drugs directed towards mutant IDH2, the NF-κB, JAK/STAT, or mTOR pathways illustrate the usefulness of genome-wide techniques to identify targets for therapy. In this review, we highlight recent advances in the molecular diagnosis and prognosis of PTCL using these genome-wide techniques.

Original languageEnglish (US)
Pages (from-to)89-100
Number of pages12
JournalBlood Reviews
Volume30
Issue number2
DOIs
StatePublished - Mar 1 2016

Fingerprint

T-Cell Lymphoma
Peripheral T-Cell Lymphoma
Genome
Natural Killer Cells
Immunophenotyping
Adult T Cell Leukemia Lymphoma
Gene Expression Profiling
Gene Expression
Therapeutics
Pharmaceutical Preparations
Genes

Keywords

  • Gene expression profiling
  • Molecular classification
  • Molecular prognosis
  • Peripheral T-cell lymphoma
  • Targeted therapy

ASJC Scopus subject areas

  • Hematology
  • Oncology

Cite this

Genomic signatures in T-cell lymphoma : How can these improve precision in diagnosis and inform prognosis? / Iqbal, Javeed; Wilcox, Ryan; Naushad Qureishi, Hina; Rohr, Joseph; Heavican, Tayla B.; Wang, Chao; Bouska, Alyssa; Fu, Kai; Chan, Wing C.; Vose, Julie Marie.

In: Blood Reviews, Vol. 30, No. 2, 01.03.2016, p. 89-100.

Research output: Contribution to journalArticle

Iqbal, Javeed ; Wilcox, Ryan ; Naushad Qureishi, Hina ; Rohr, Joseph ; Heavican, Tayla B. ; Wang, Chao ; Bouska, Alyssa ; Fu, Kai ; Chan, Wing C. ; Vose, Julie Marie. / Genomic signatures in T-cell lymphoma : How can these improve precision in diagnosis and inform prognosis?. In: Blood Reviews. 2016 ; Vol. 30, No. 2. pp. 89-100.
@article{477dfeab25104a3ca05a2e50bf550703,
title = "Genomic signatures in T-cell lymphoma: How can these improve precision in diagnosis and inform prognosis?",
abstract = "The novel genetic information gained from genome-wide high throughput techniques has greatly improved our understanding of peripheral T-cell lymphoma (PTCL). PTCL consists of numerous distinct entities and is currently diagnosed using a combination of clinical and morphologic features and immunophenotyping together with limited molecular assays leading to an often fragmented, complicated diagnostic system. The diagnosis of many cases is challenging even for expert hematopathologists and more than a third of the cases cannot be further classified and thus put into the PTCL-NOS category. Gene expression profiling (GEP) has significantly improved the molecular classification of PTCLs and identified robust molecular signatures for common nodal subtypes of PTCL including angioimmunoblastic T-cell lymphoma (AITL), anaplastic T-cell lymphoma (ALCL), adult T-cell leukemia/lymphoma (ATLL) and extra-nodal NK/T cell lymphoma (ENKTL). These studies also led to identification of novel molecular subtypes with distinct prognosis, that otherwise could not be identified by conventional methods. Integration of massive sequencing strategies and gene expression has characterized driver genetic alterations in common subtypes like AITL, ALCL, ENKTL and other PTCLs. These studies have identified oncogenic pathways and genes affected in specific disease subtypes that can be potentially targeted by specific therapies. Novel treatment options with FDA approved drugs directed towards mutant IDH2, the NF-κB, JAK/STAT, or mTOR pathways illustrate the usefulness of genome-wide techniques to identify targets for therapy. In this review, we highlight recent advances in the molecular diagnosis and prognosis of PTCL using these genome-wide techniques.",
keywords = "Gene expression profiling, Molecular classification, Molecular prognosis, Peripheral T-cell lymphoma, Targeted therapy",
author = "Javeed Iqbal and Ryan Wilcox and {Naushad Qureishi}, Hina and Joseph Rohr and Heavican, {Tayla B.} and Chao Wang and Alyssa Bouska and Kai Fu and Chan, {Wing C.} and Vose, {Julie Marie}",
year = "2016",
month = "3",
day = "1",
doi = "10.1016/j.blre.2015.08.003",
language = "English (US)",
volume = "30",
pages = "89--100",
journal = "Blood Reviews",
issn = "0268-960X",
publisher = "Churchill Livingstone",
number = "2",

}

TY - JOUR

T1 - Genomic signatures in T-cell lymphoma

T2 - How can these improve precision in diagnosis and inform prognosis?

AU - Iqbal, Javeed

AU - Wilcox, Ryan

AU - Naushad Qureishi, Hina

AU - Rohr, Joseph

AU - Heavican, Tayla B.

AU - Wang, Chao

AU - Bouska, Alyssa

AU - Fu, Kai

AU - Chan, Wing C.

AU - Vose, Julie Marie

PY - 2016/3/1

Y1 - 2016/3/1

N2 - The novel genetic information gained from genome-wide high throughput techniques has greatly improved our understanding of peripheral T-cell lymphoma (PTCL). PTCL consists of numerous distinct entities and is currently diagnosed using a combination of clinical and morphologic features and immunophenotyping together with limited molecular assays leading to an often fragmented, complicated diagnostic system. The diagnosis of many cases is challenging even for expert hematopathologists and more than a third of the cases cannot be further classified and thus put into the PTCL-NOS category. Gene expression profiling (GEP) has significantly improved the molecular classification of PTCLs and identified robust molecular signatures for common nodal subtypes of PTCL including angioimmunoblastic T-cell lymphoma (AITL), anaplastic T-cell lymphoma (ALCL), adult T-cell leukemia/lymphoma (ATLL) and extra-nodal NK/T cell lymphoma (ENKTL). These studies also led to identification of novel molecular subtypes with distinct prognosis, that otherwise could not be identified by conventional methods. Integration of massive sequencing strategies and gene expression has characterized driver genetic alterations in common subtypes like AITL, ALCL, ENKTL and other PTCLs. These studies have identified oncogenic pathways and genes affected in specific disease subtypes that can be potentially targeted by specific therapies. Novel treatment options with FDA approved drugs directed towards mutant IDH2, the NF-κB, JAK/STAT, or mTOR pathways illustrate the usefulness of genome-wide techniques to identify targets for therapy. In this review, we highlight recent advances in the molecular diagnosis and prognosis of PTCL using these genome-wide techniques.

AB - The novel genetic information gained from genome-wide high throughput techniques has greatly improved our understanding of peripheral T-cell lymphoma (PTCL). PTCL consists of numerous distinct entities and is currently diagnosed using a combination of clinical and morphologic features and immunophenotyping together with limited molecular assays leading to an often fragmented, complicated diagnostic system. The diagnosis of many cases is challenging even for expert hematopathologists and more than a third of the cases cannot be further classified and thus put into the PTCL-NOS category. Gene expression profiling (GEP) has significantly improved the molecular classification of PTCLs and identified robust molecular signatures for common nodal subtypes of PTCL including angioimmunoblastic T-cell lymphoma (AITL), anaplastic T-cell lymphoma (ALCL), adult T-cell leukemia/lymphoma (ATLL) and extra-nodal NK/T cell lymphoma (ENKTL). These studies also led to identification of novel molecular subtypes with distinct prognosis, that otherwise could not be identified by conventional methods. Integration of massive sequencing strategies and gene expression has characterized driver genetic alterations in common subtypes like AITL, ALCL, ENKTL and other PTCLs. These studies have identified oncogenic pathways and genes affected in specific disease subtypes that can be potentially targeted by specific therapies. Novel treatment options with FDA approved drugs directed towards mutant IDH2, the NF-κB, JAK/STAT, or mTOR pathways illustrate the usefulness of genome-wide techniques to identify targets for therapy. In this review, we highlight recent advances in the molecular diagnosis and prognosis of PTCL using these genome-wide techniques.

KW - Gene expression profiling

KW - Molecular classification

KW - Molecular prognosis

KW - Peripheral T-cell lymphoma

KW - Targeted therapy

UR - http://www.scopus.com/inward/record.url?scp=84940092892&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84940092892&partnerID=8YFLogxK

U2 - 10.1016/j.blre.2015.08.003

DO - 10.1016/j.blre.2015.08.003

M3 - Article

VL - 30

SP - 89

EP - 100

JO - Blood Reviews

JF - Blood Reviews

SN - 0268-960X

IS - 2

ER -